Ruffer LLP’s Adicet Bio ACET Stock Holding History

Ruffer LLP’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-2,679	Closed	-$313K	–	84
2020 Q1	$313K	Hold	2,679	–	–	0.01%	67
2019 Q4	$446K	Buy	2,679 +2,233	+501%	+$1.13M	0.01%	67
2019 Q3	$443K	Sell	446 -604	-58%	-$674K	0.01%	76
2019 Q2	$1.2M	Buy	+1,050	New	+$952K	0.03%	64

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Ruffer LLP's ACET Position: Q2 2020 in Review

Ruffer LLP sold out of Adicet Bio (ACET) in Q2 2020, closing a stake of 2,679 shares — an estimated $313K sold.

Ruffer LLP first reported a position in ACET in Q2 2019 and held it in 4 quarters. The position peaked at $1.2M in Q2 2019. 53 funds tracked by Wall St. Rank hold ACET as of Q2 2020.

Ruffer LLP reported no remaining Adicet Bio position as of Q2 2020 after selling out during the quarter.
Ruffer LLP sold 2,679 Adicet Bio shares in Q2 2020, an estimated $313K.
Ruffer LLP first reported a position in Adicet Bio in Q2 2019 and held it in 4 quarters.
Ruffer LLP's Adicet Bio position peaked at $1.2M in Q2 2019.
53 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2020.

Based on Ruffer LLP's 13F filing for Q2 2020, filed 4 Aug 2020.